Since first approval in 1995, it is known that MMF is well-tolerated, with few severe complications, and is effective in many autoimmune disorders, including lupus, systemic sclerosis, myasthenia gravis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease (15–21). This evidence concerns the gene MOG and neuromyelitis optica.